Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$33.84 USD
-0.14 (-0.41%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $33.84 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.84 USD
-0.14 (-0.41%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $33.84 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Uncertainty Looms Large Over Generic Drug Industry Players
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 33.33% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals (SUPN) Q4 Earnings Beat Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock?
by Zacks Equity Research
Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?
by Zacks Equity Research
Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.
Supernus Pharmaceuticals (SUPN) Q2 Earnings Top Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 8.93% and -3.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
by Christopher Vargas
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
Supernus Pharmaceuticals (SUPN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -22.73% and -18.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus' ADHD Candidate Positive in 4th Phase III Study
by Zacks Equity Research
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
MYL vs. SUPN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MYL vs. SUPN: Which Stock Is the Better Value Option?
Supernus Pharmaceuticals (SUPN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 20.93% and 2.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals (SUPN): Moving Average Crossover Alert
by Zacks Equity Research
Supernus Pharmaceuticals, Inc. (SUPN) could be a stock to avoid from a technical perspective
New Strong Sell Stocks for October 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 29.55% and -1.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Supernus (SUPN) Stock Options
by Zacks Equity Research
Supernus (SUPN) needs investors to pay close attention to the stock based on moves in the options market lately.
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
by Zacks Equity Research
Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.
Supernus Pharmaceuticals (SUPN) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Supernus Pharmaceuticals, Inc. (SUPN) moved big last session, as its shares jumped over 6% on the day.
Stocks Most Likely to Beat Earnings for the Week of December 12th
by Zacks Equity Research
Here are four stocks that are likely to beat earnings for the week of December 12th: